Becton, Dickinson and Company (NYSE:BDX) EVP Roland Goette Sells 2,438 Shares

Becton, Dickinson and Company (NYSE:BDX) EVP Roland Goette sold 2,438 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total value of $440,887.92. Following the sale, the executive vice president owned 14,856 shares of the company’s stock, valued at $2,686,559.04. This represents a 14.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Becton, Dickinson and Company Trading Up 1.0%

NYSE:BDX opened at $183.14 on Thursday. The stock has a market cap of $50.46 billion, a price-to-earnings ratio of 55.16, a price-to-earnings-growth ratio of 12.79 and a beta of 0.19. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $187.35. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. The business’s 50-day simple moving average is $156.55 and its 200 day simple moving average is $161.69.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.84% and a net margin of 4.52%.The company had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same period in the previous year, the business earned $3.68 EPS. Becton, Dickinson and Company’s revenue for the quarter was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, sell-side analysts predict that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be issued a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 126.51%.

Institutional Investors Weigh In On Becton, Dickinson and Company

Large investors have recently added to or reduced their stakes in the stock. Imprint Wealth LLC acquired a new position in shares of Becton, Dickinson and Company during the third quarter valued at $25,000. Steph & Co. increased its holdings in shares of Becton, Dickinson and Company by 95.6% in the 4th quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 65 shares during the period. SHP Wealth Management bought a new stake in Becton, Dickinson and Company in the 4th quarter valued at about $26,000. Prosperity Bancshares Inc acquired a new position in Becton, Dickinson and Company during the 4th quarter valued at about $29,000. Finally, WPG Advisers LLC boosted its stake in Becton, Dickinson and Company by 64.2% during the 4th quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 61 shares during the period. 86.97% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

BDX has been the topic of several research reports. UBS Group started coverage on Becton, Dickinson and Company in a research report on Tuesday, July 28th. They set a “buy” rating and a $190.00 price target on the stock. Bank of America decreased their price objective on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a report on Friday, June 12th. TD Cowen increased their target price on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a report on Wednesday, August 5th. Citigroup raised their price target on shares of Becton, Dickinson and Company from $198.00 to $204.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Finally, Royal Bank Of Canada lifted their price target on shares of Becton, Dickinson and Company from $175.00 to $180.00 and gave the company a “sector perform” rating in a report on Friday, August 7th. Eight investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Hold” and an average price target of $185.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.